Figure 1. Combined targeting of SMO and BRD4 as a potential therapeutic strategy against melanoma.

(A) Schematic diagram of the Hedgehog signaling, showing inhibition of the canonical pathway with SMO inhibitors and blockade of non-canonical activation of GLI1 with BRD4 inhibitors or PROTAC-based degraders. (B) Schematic diagram depicting therapeutic interventions in melanoma patients with high and low expression of SOX2/GLI1.